Guido Oelkers will remain active in his CEO role until the end January 2027 at the latest. The Board of Directors will immediately begin a process to secure a structured transition and to appoint a new CEO.

“On behalf of the Board, I would like to sincerely thank Guido for nearly 10 years of dedication and leadership at Sobi. Under his stewardship, the company has strengthened its rare disease portfolio, delivered strong financial performance and he leaves Sobi well positioned for its next growth chapter” says David Meek, Chairman of the board of Directors. “The Board has now begun the process of identifying a successor to ensure continuity and a smooth transition for our business and our employees.”

“Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team, from advancing our pipeline, expanding our global footprint, and growing Sobi to be a leader in rare diseases” said Guido Oelkers, President and CEO of Sobi. “Sobi is strongly positioned for sustained growth, and I am confident that, working closely with the Board, we will ensure a structured and seamless transition to new leadership. I remain fully committed to Sobi until the end of my tenure.”